David Garvey

6579863, Jun 17, 2003

Oct 13, 2000

09/689851

David S. Garvey - Waltham MA
L. Gordon Letts - Dover MA
H. Burt Renfroe - Wellesley MA
Stewart K. Richardson - Ashford CT

Nitromed, Inc. - Bedford MA

A61K 3156

514171, 514178, 514179, 514180, 514174

Disclosed are (i) compounds of a steroid, a -agonist, an anticholinergic, a mast cell stabilizer and a phosphodiesterase (PDE) inhibitor directly or indirectly linked to a NO or NO group or a group which stimulates endogenous production of NO or EDRF in vivo; (ii) compositions of steroids, -agonists, anticholinergics, mast cell stabilizers and PDE inhibitors, which can optionally be substituted with at least one NO or NO moiety or a group which stimulates endogenous production of NO or EDRF in vivo, and a compound that donates, transfers or releases nitric oxide as a charged species, i. e. , nitrosonium (NO ) or nitroxyl (NO ), or as the neutral species, nitric oxide (NOâ) or that stimulates endogenous production of NO or EDRF in vivo; and (iii) uses for them in preventing and/or treating respiratory disorders.

6593347, Jul 15, 2003

Aug 27, 2001

09/938560

Upul K. Bandarage - Newton MA
Qing Dong - Cambridge MA
Xinqin Fang - Chestnut Hill MA
David S. Garvey - Dover MA
Gregory J. Mercer - Stoughton MA
Stewart K. Richardson - Tolland CT
Joseph D. Schroeder - Dedham MA
Tiansheng Wang - Concord MA

NitroMed, Inc. - Bedford MA

A61K 31445

514327, 5142262, 514291, 514365, 514374, 514375, 514378, 514393, 514404, 514406, 514411, 514416, 514419, 514423, 514427, 514428, 514431, 514448, 514450, 514532, 514539, 514545, 514621, 514640, 514658, 514676, 514709, 514719

The present invention describes novel nitrosated and/or nitrosylated nonsteroidal antiinflammatory compounds, and novel compositions comprising at least one nitrosated and/or nitrosylated nonsteroidal antiinflammatory compound, and, optionally, at least one compound that donates, transfers or releases nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor, stimulates endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase. The present invention also provides methods for treating, preventing and/or reducing inflammation, pain, and fever; decreasing or reversing the gastrointestinal, renal and other toxicities resulting from the use of nonsteroidal antiinflammatory drugs; treating and/or preventing gastrointestinal disorders; treating inflammatory disease states and disorders; and treating and/or preventing ophthalmic diseases or disorders.

6417162, Jul 9, 2002

May 7, 1999

09/306809

David S. Garvey - Dover MA
Joseph D. Schroeder - Boston MA
Inigo Saenz de Tejada - Madrid, ES

NitroMed, Inc. - Bedford MA

A01N 4354

514 2, 514258, 514259, 514260, 514280, 514423, 514562, 514644, 514645

The present invention is directed to nitrosated or nitrosylated -adrenergic receptor antagonists, compositions comprising -adrenergic receptor antagonists that are optionally substituted with at least one NO or NO moiety and compounds that donate, transfer or release nitric oxide or elevate levels of endogenous endothelium-derived relaxing factor, and methods for treating sexual dysfunctions in males and females.

6649629, Nov 18, 2003

Dec 22, 2000

09/741816

Upul K. Bandarage - Newton MA
Xinqin Fang - Lexington MA
David S. Garvey - Dover MA
L. Gordon Letts - Dover MA
Joseph D. Schroeder - Dedham MA
Sang William Tam - Dover MA

Nitromed, Inc. - Bedford MA

C07D207325

514326, 514378, 514406, 546209, 548247, 548248, 5483751, 548561

The present invention describes novel nitrosated and/or nitrosylated cyclooxygenase 2 (COX-2) inhibitors and novel compositions comprising at least one nitrosated and/or nitrosylated cyclooxygenase 2 (COX-2) inhibitor, and, optionally, at least one compound that donates, transfers or releases nitric oxide, stimulates endogenous synthesis of nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor or is a substrate for nitric oxide synthase, and/or optionally, at least one therapeutic agent, such as, steroids, nonsteroidal antiinflammatory compounds (NSAID), 5-lipoxygenase (5-LO) inhibitors, leukotriene B (LTB ) receptor antagonists, leukotriene A (LTA ) hydrolase inhibitors, 5-HT agonists, 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) inhibitors, H antagonists, antineoplastic agents, antiplatelet agents, decongestants, diuretics, sedating or non-sedating anti-histamines, inducible nitric oxide synthase inhibitors, opioids, analgesics, inhibitors, proton pump inhibitors, isoprostane inhibitors, and mixtures thereof. The present invention also provides novel compositions comprising at least one parent COX-2 inhibitor and at least one nitric oxide donor, and, optionally, at least one therapeutic agent. The present invention also provides kits and methods for treating inflammation, pain and fever; for treating and/or improving the gastrointestinal properties of COX-2 inhibitors; for facilitating wound healing; for treating and/or preventing renal toxicity; and for treating and/or preventing other disorders resulting from elevated levels of cyclooxygenase-2.

6656966, Dec 2, 2003

Jun 22, 2001

09/886494

David S. Garvey - Dover MA
L. Gordon Letts - Dover MA
Chia-En Lin - Burlington MA
Stewart K. Richardson - Tolland CT
Tiansheng Wang - Concord MA

NitroMed, Inc. - Bedford MA

A61K 31337

514449, 549510, 549511

The present invention describes novel nitrosated and/or nitrosylated taxanes, and novel compositions comprising at least one nitrosated and/or nitrosylated taxane, and, optionally, at least one compound that donates, transfers or releases nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor, stimulates endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase and/or at least one therapeutic agent. The present invention also provides novel compositions comprising at least one taxane and at least one compound that donates, transfers or releases nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor, stimulates endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase and/or at least one therapeutic agent. The compounds and compositions of the present invention can also be bound to a matrix. The present invention also provides methods for treating or preventing cardiovascular diseases and disorders, autoimmune diseases, pathological conditions resulting from abnormal cell proliferation, polycystic kidney disease, inflammatory disease, preserving organs and/or tissues or to inhibit wound contraction, particularly the prophylactic and/or therapeutic treatment of restenosis, by administering nitrosated and/or nitrosylated taxane or parent taxanes in combination with nitric oxide donors that are capable of releasing nitric oxide or indirectly delivering or transferring nitric oxide to targeted sites under physiological conditions.

6417207, Jul 9, 2002

May 12, 2000

09/570727

David S. Garvey - Dover MA
Inigo Saenz de Tejada - Madrid, ES

NitroMed, Inc. - Bedford MA

A61K 3144

514355, 546314, 546315, 546316, 546329, 546330, 514354, 514357

The present invention describes novel nitrosated and/or nitrosylated potassium channel activators, and novel compositions comprising at least one nitrosated and/or nitrosylated potassium channel activator, and, optionally, at least one compound that donates, transfers or releases nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor, stimulates endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase and/or at least one vasoactive agent. The present invention also provides novel compositions comprising at least one potassium channel activator, and at least one compound that donates, transfers or releases nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor, stimulates endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase and/or at least one vasoactive agent. The present invention also provides methods for treating or preventing sexual dysfunctions in males and females, for enhancing sexual responses in males and females, and for treating or preventing cardiovascular disorders, cerebrovascular disorders, hypertension, asthma, baldness, urinary incontinence, epilepsy, sleep disorders, gastrointestinal disorders, migraines, irritable bowel syndrome and sensitive skin.

6693122, Feb 17, 2004

May 28, 2002

10/154916

David S. Garvey - Dover MA
Inigo Saenz de Tejada - Madrid, ES

NitroMed, Inc. - Bedford MA

A61K 3144

514353, 546306

The present invention describes novel nitrosated and/or nitrosylated potassium channel activators, and novel compositions comprising at least one nitrosated and/or nitrosylated potassium channel activator, and, optionally, at least one compound that donates, transfers or releases nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor, stimulates endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase and/or at least one vasoactive agent. The present invention also provides novel compositions comprising at least one potassium channel activator, and at least one compound that donates, transfers or releases nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor, stimulates endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase and/or at least one vasoactive agent. The present invention also provides methods for treating or preventing sexual dysfunctions in males and females, for enhancing sexual responses in males and females, and for treating or preventing cardiovascular disorders, cerebrovascular disorders, hypertension, asthma, baldness, urinary incontinence, epilepsy, sleep disorders, gastrointestinal disorders, migraines, irritable bowel syndrome and sensitive skin.

6706724, Mar 16, 2004

Dec 21, 2001

10/024046

Subhash P. Khanapure - Clinton MA
David S. Garvey - Dover MA
Richard A. Earl - Westford MA
Maiko Ezawa - Acton MA
Xinqin Fang - Lexington MA
Ricky D. Gaston - Malden MA

NitroMed, Inc. - Bedford MA

A61K 31435

514277, 514336, 514340, 514342, 514365, 514374, 514443, 514469, 546 1, 546114, 546115, 546208, 548146, 548152, 548153, 548217, 549229, 549396, 549398, 549430, 549462, 549469, 549472

The invention describes novel substituted aryl compounds that are cyclooxygenase 2 (COX-2) selective inhibitors and novel compositions comprising at least one cyclooxygenase 2 (COX-2) selective inhibitor, and, optionally, at least one compound that donates, transfers or releases nitric oxide, stimulates endogenous synthesis of nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor or is a substrate for nitric oxide synthase, and/or, optionally, at least one therapeutic agent, such as, steroids, nonsterodal antiinflammatory compounds (NSAID), 5-lipoxygenase (5-LO) inhibitors, leukotriene B (LTB ) receptor antagonists, leukotriene A (LTA ) hydrolase inhibitors, 5-HT agonists, 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) inhibitors, H antagonists, antineoplastic agents, antiplatelet agents, thrombin inhibitors, thromboxane inhibitors, decongestants, diuretics, sedating or non-sedating anti-histamines, inducible nitric oxide synthase inhibitors, opioids, analgesics, inhibitors, proton pump inhibitors, isoprostane inhibitors, and mixtures thereof. The invention also provides novel kits comprising at least one COX-2 selective inhibitor, and, optionally, at least one nitric oxide donor, and/or, optionally, at least one therapeutic agent. The novel cyclooxygenase 2 selective inhibitors of the invention can be optionally nitrosated and/or nitrosylated.